Redx Pharma concludes trading on JP Jenkins as of 1 May 2025
Redx Presents Preclinical Data on RXC008, a Potential First-in-Class Therapy to Treat Fibrostenotic Crohn’s Disease, at the UEG Week

Trinity Delta Report: Redx Pharma

Redx to Exhibit Three Posters at AACR Annual Meeting

PROPOSED CANCELLATION OF ADMISSION TO TRADING

Result of Annual General Meeting
